Clinical Trial Update: Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating inhaled TPI 1100 in healthy volunteers for safety, tolerability, pharmacodynamics and pharmacokinetics has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TPI 1100

Snippet

Sponsor: Syntara | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: WITHDRAWN